Orthopediatrics Corp (KIDS) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Orthopediatrics Corp (NASDAQ:KIDS) have earned an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $27.00.
A number of equities research analysts have recently weighed in on KIDS shares. BidaskClub upgraded shares of Orthopediatrics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 31st. Zacks Investment Research downgraded shares of Orthopediatrics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 14th. Finally, ValuEngine upgraded shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd.
KIDS stock traded down $0.83 during mid-day trading on Monday, hitting $28.88. 28,673 shares of the company were exchanged, compared to its average volume of 44,486. The company has a quick ratio of 3.23, a current ratio of 5.67 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $380.76 million and a PE ratio of -5.07. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $39.81.
In related news, Director Kevin Unger sold 1,000 shares of Orthopediatrics stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $33.22, for a total value of $33,220.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 9,525 shares of Orthopediatrics stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $33.73, for a total transaction of $321,278.25. The disclosure for this sale can be found here. 46.10% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Orthopediatrics by 18.8% during the 3rd quarter. BlackRock Inc. now owns 405,478 shares of the company’s stock valued at $14,856,000 after buying an additional 64,282 shares in the last quarter. PNC Financial Services Group Inc. purchased a new stake in shares of Orthopediatrics during the 3rd quarter valued at approximately $448,000. EAM Global Investors LLC purchased a new stake in shares of Orthopediatrics during the 3rd quarter valued at approximately $1,737,000. EAM Investors LLC lifted its stake in shares of Orthopediatrics by 118.8% during the 3rd quarter. EAM Investors LLC now owns 68,217 shares of the company’s stock valued at $2,499,000 after buying an additional 37,045 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Orthopediatrics during the 3rd quarter valued at approximately $207,000. 40.22% of the stock is currently owned by institutional investors and hedge funds.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.